Biotech Values

[DewDiligence]

BMY responded to the FDA’s Belatacept CRL, but the FDA told BMY a decision on the BLA is on hold until BMY brings manufacturing at its Puerto Rico plant into compliance. This will delay a decision on the Belatacept BLA until at least 2Q11. (Source: BMY’s 3Q10 CC)